LakeShore Biopharma Co (LakeShore Biopharma Co) Cash, Cash Equivalents, Marketable Securities : $35.61 Mil (As of Sep. 2023)

View and export this data going back to 2023. Start your Free Trial

What is LakeShore Biopharma Co Cash, Cash Equivalents, Marketable Securities?

LakeShore Biopharma Co's quarterly cash, cash equivalents, marketable securities increased from Sep. 2022 ($32.31 Mil) to Mar. 2023 ($53.71 Mil) but then stayed the same from Mar. 2023 ($53.71 Mil) to Sep. 2023 ($35.61 Mil).

LakeShore Biopharma Co's annual cash, cash equivalents, marketable securities declined from Mar. 2021 ($59.97 Mil) to Mar. 2022 ($42.72 Mil) but then increased from Mar. 2022 ($42.72 Mil) to Mar. 2023 ($53.71 Mil).

LakeShore Biopharma Co Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for LakeShore Biopharma Co's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LakeShore Biopharma Co Cash, Cash Equivalents, Marketable Securities Chart

LakeShore Biopharma Co Annual Data

Trend

Mar21

Mar22

Mar23

Cash, Cash Equivalents, Marketable Securities

59.97

42.72

53.71

LakeShore Biopharma Co Semi-Annual Data
	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial			-	42.72	32.31	53.71	35.61

LakeShore Biopharma Co Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

LakeShore Biopharma Co (NAS:LSB) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

LakeShore Biopharma Co Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of LakeShore Biopharma Co's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

LakeShore Biopharma Co (LakeShore Biopharma Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LakeShore Biopharma Co Ltd (NAS:LSB) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

H6Z:Germany

Address

38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629

Website

https://www.yishengbio.com

YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is also conducting the production and sale of YSJA, a rabies vaccine, the first aluminium-free lyophilized rabies vaccine that was launched in China. It has one operating segment, which is the development, production, marketing and sale of biopharmaceutical products.